CMS announced that, beginning October 29, the long-stay antipsychotic measure used within long-term care will be calculated not only using Minimum Data Set (MDS) data, but also by incorporating Medicare and Medicaid claims and encounter data. According to the agency, this expanded methodology will increase the reported proportion of long-stay nursing home residents receiving an antipsychotic from 14.64% to 16.98%. CMS states that this new approach will result in “improved accuracy.” Additional rationale for the update is outlined on page 3 of the memo. Unfortunately, this change does not alleviate Project Pause’s (AAPP is a coalition member) longstanding concerns with the measure. Rather than signaling a willingness to retire or meaningfully revise the long-stay antipsychotic use measure in the Nursing Home Care Compare Five-Star Quality Rating System, CMS is choosing to incorporate additional data without addressing the underlying flaws of the measure and the myriad unintended consequences on patient quality of care that Project PAUSE has repeatedly raised. The Project Pause is presently strategizing on potential next steps.